EXHIBITION PREVIEW
BSMT Annual Microbiology Conference: exhibition preview 2024
Pathology in Practice is once again pleased to support the British Society for Microbial Technology’s Annual Microbiology Conference with a preview of those companies participating in the accompanying trade exhibition.
Becton Dickinson BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop
the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organisations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance
outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
www.bd.com
BioConnections The eazyplex test system represents a significant advancement in infectious sciences, offering rapid and precise differential diagnosis of critical infectious pathogens. Validated by numerous publications and widely adopted in clinical laboratories throughout the UK and Europe, this state-of-the-art technology integrates isothermal amplification to deliver sensitive and reliable results. Recent research highlights the
Becton Dickinson.
system’s versatility in combining assays for pathogens, such as the hypervirulent Klebsiella pneumoniae (hvKp) – associated virulence genes and beta- lactamase detection.
WWW.PATHOLOGYINPRACTICE.COM APRIL 2024
BioConnections.
The eazyplex system is closed to minimise contamination, has just five minutes hands-on time with results in under 30 minutes. It also boats USB data export and intuitive operation for multitasking. The testing system’s compact platform enables near-patient testing using ready-to-use, lyophilised reagents. Its high sensitivity and substantial reduction in turnaround time (TAT) allow clinicians to simultaneously make informed decisions based on clinical symptoms and diagnostic results. Targeting a wide array of infectious diseases, including ARM organisms, Candida auris, Clostridium difficile, EHECs, MRSA – PVL toxin, and sepsis- causing pathogens, the eazyplex test operates directly from various sample materials without the need for DNA/RNA extraction.
www.bioconnections.co.uk
23
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57
